|Description:||1. Caudatin exerts antiproliferative effects on human hepatocellular carcinoma SMMC7721 cells.|
2. Caudatin has anticancer activity, due partly to its inhibition of cell proliferation and induction of apoptosis in cancer cells through caspase activation.
3. Caudatin exhibits significantly inhibitory activity against HBV DNA replication with IC50 values in the range of 2.82-7.48 μM.
4. Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis by targeting GSK3β/β-catenin pathway and suppressing VEGF production.
|Targets:||VEGFR | GSK-3 | HBV|
|Source:||The roots of Cynanchum otophyllum|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.0383 mL||10.1916 mL||20.3832 mL||40.7664 mL||50.958 mL|
|5 mM||0.4077 mL||2.0383 mL||4.0766 mL||8.1533 mL||10.1916 mL|
|10 mM||0.2038 mL||1.0192 mL||2.0383 mL||4.0766 mL||5.0958 mL|
|50 mM||0.0408 mL||0.2038 mL||0.4077 mL||0.8153 mL||1.0192 mL|
|100 mM||0.0204 mL||0.1019 mL||0.2038 mL||0.4077 mL||0.5096 mL|
Oncol Rep. 2013 Dec;30(6):2923-8.
|Caudatin inhibits human hepatoma cell growth and metastasis through modulation of the Wnt/β-catenin pathway.[Pubmed: 24064800]|
|The results showed that Caudatin impaired the cell viability and inhibited the growth of SMMC-7721 cells in a time- and dose-dependent manner and resulted in cell cycle arrest in the G2 phase. In addition, SMMC-7721 cells, treated with Caudatin exhibited typical characteristics of apoptosis. Furthermore, Caudatin treatment resulted in a decrease in β-catenin and GSK3β in SMMC-7721 cells, with a concomitant reduction in metastatic capability and expression of Wnt signaling pathway targeted genes including cox-2, mmp-2 and mmp-9. Our findings revealed that Caudatin inhibits human hepatoma cell growth and metastasis by targeting the GSK3β/β-catenin pathway and suppressing VEGF production.|
J Cell Biochem. 2012 Nov;113(11):3403-10.
|Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis through modulating GSK3β/β-catenin pathway.[Pubmed: 22678744]|
|In this study, we investigate the anti-cancer activity of Caudatin in carcinomic human alveolar basal epithelial cell line A549 and anti-angiogenic activity in human umbilical vein endothelial cells (HUVECs). Our findings suggest that Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis by targeting GSK3β/β-catenin pathway and suppressing VEGF production.|
Med Chem. 2015;11(2):165-79.
|Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors.[Pubmed: 25181984]|
|Thirty-nine Caudatin analogs were designed and synthesized. Their anti-hepatitis B virus (HBV) activities were evaluated in vitro. Among them, twenty-three compounds showed much better anti-HBV activity than Caudatin, and eleven compounds significantly inhibited the HBV DNA replication with IC50 values < 10 μM.|